A Therapeutic Trial for Safety and Preliminary Efficacy of the Combination of Axitinib and Seleniomethionine (SLM) for Adult Patients With Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC)

Trial Profile

A Therapeutic Trial for Safety and Preliminary Efficacy of the Combination of Axitinib and Seleniomethionine (SLM) for Adult Patients With Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Nov 2016

At a glance

  • Drugs Axitinib (Primary) ; Selenomethionine
  • Indications Renal cell carcinoma
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Nov 2016 Status changed from suspended to recruiting.
    • 24 Oct 2016 Planned End Date changed from 1 Sep 2018 to 1 Sep 2019.
    • 24 Oct 2016 Status changed from recruiting to suspended.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top